Man­u­fac­tur­ing roundup: As­traZeneca and Sam­sung ink $350M deal; Michi­gan CD­MO com­pletes ex­pan­sion

Sam­sung’s biotech arm and As­traZeneca are look­ing to work to­geth­er on a con­tract man­u­fac­tur­ing agree­ment.

Ac­cord­ing to a re­port from Ko­rea’s Yon­hap News Agency, Sam­sung Bi­o­log­ics has signed a let­ter of in­tent with As­traZeneca on a co­op­er­a­tion deal val­ued at an es­ti­mat­ed $350 mil­lion, but no oth­er de­tails on the deal were avail­able.

Sam­sung Bi­o­log­ics told Yon­hap that the com­pa­nies ex­changed a sep­a­rate let­ter of in­tent last year to col­lab­o­rate on bio­phar­ma­ceu­ti­cal man­u­fac­tur­ing, but now the col­lab­o­ra­tion has grown due to in­creased de­mand from As­traZeneca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.